Sihuan Pharmaceutical Holdings Group Balance Sheet Health
Financial Health criteria checks 3/6
Sihuan Pharmaceutical Holdings Group has a total shareholder equity of CN¥5.1B and total debt of CN¥1.2B, which brings its debt-to-equity ratio to 22.9%. Its total assets and total liabilities are CN¥11.5B and CN¥6.4B respectively.
Key information
22.9%
Debt to equity ratio
CN¥1.17b
Debt
Interest coverage ratio | n/a |
Cash | CN¥4.37b |
Equity | CN¥5.14b |
Total liabilities | CN¥6.40b |
Total assets | CN¥11.54b |
Recent financial health updates
Health Check: How Prudently Does Sihuan Pharmaceutical Holdings Group (HKG:460) Use Debt?
Oct 31Does Sihuan Pharmaceutical Holdings Group (HKG:460) Have A Healthy Balance Sheet?
Oct 11Sihuan Pharmaceutical Holdings Group (HKG:460) Seems To Use Debt Rather Sparingly
Sep 26Does Sihuan Pharmaceutical Holdings Group (HKG:460) Have A Healthy Balance Sheet?
Dec 21Recent updates
Here's Why It's Unlikely That Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) CEO Will See A Pay Rise This Year
May 31Investors Still Waiting For A Pull Back In Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
May 27A Look At The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Dec 05Health Check: How Prudently Does Sihuan Pharmaceutical Holdings Group (HKG:460) Use Debt?
Oct 31Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Aug 19Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Apr 21Is Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Worth HK$0.8 Based On Its Intrinsic Value?
Nov 03Does Sihuan Pharmaceutical Holdings Group (HKG:460) Have A Healthy Balance Sheet?
Oct 11Is There An Opportunity With Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) 34% Undervaluation?
Jun 21Estimating The Intrinsic Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Mar 09A Look At The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Nov 28Sihuan Pharmaceutical Holdings Group (HKG:460) Seems To Use Debt Rather Sparingly
Sep 26We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) CEO For Now
Jun 22How Does Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Fare As A Dividend Stock?
May 11Sihuan Pharmaceutical Holdings Group's (HKG:460) Shareholders May Want To Dig Deeper Than Statutory Profit
Mar 30How Much Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Do Insiders Own?
Mar 07Should You Buy Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) For Its Dividend?
Feb 07Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Jan 11Does Sihuan Pharmaceutical Holdings Group (HKG:460) Have A Healthy Balance Sheet?
Dec 21Why Sihuan Pharmaceutical Holdings Group's (HKG:460) CEO Pay Matters
Dec 07Financial Position Analysis
Short Term Liabilities: 460's short term assets (CN¥6.2B) exceed its short term liabilities (CN¥4.1B).
Long Term Liabilities: 460's short term assets (CN¥6.2B) exceed its long term liabilities (CN¥2.3B).
Debt to Equity History and Analysis
Debt Level: 460 has more cash than its total debt.
Reducing Debt: 460's debt to equity ratio has increased from 0.7% to 22.9% over the past 5 years.
Debt Coverage: 460's debt is not well covered by operating cash flow (17%).
Interest Coverage: Insufficient data to determine if 460's interest payments on its debt are well covered by EBIT.